Hypertension and diabetes;Hypertension et diabète

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 572-577

  Krzesinski, J M ^a,b   Weekers, L ^b  

^a Service de Néphrologie   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular risk; Diabetes mellitus; Hypertension; Insulin resistance; Nephropathy; Treatment

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; LISINOPRIL; LOSARTAN; NITRENDIPINE; RAMIPRIL; TRANDOLAPRIL; VERAPAMIL;

ANGINA PECTORIS; ARTERY DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET; EVALUATION; EXERCISE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPHYLAXIS; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; INSULIN RESISTANCE; RISK FACTORS;

EID: 21744451972     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Sowers J.R.- Treatment of hypertension in patients with diabetes. Arch Intern Med, 2004, 164, 1850-1857.
2. Franklin S.- Do diabetes and hypertension interact to accelerate vascular ageing? J Hypertens, 2002, 20, 1693-1698.
3. Tuomilehto J, Lindstrom J, Erikssson J, Valle T., et al.-Prevention of type 2 diabetes mellitus by changes in life-style among subjects with impaired glucose tolerance. N Engl J Med, 2001, 344, 1343-1350
4. Yusuf S, Hawken S, Ounpuu S, et al.- Effet of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004, 364, 937-952.
5. 2003 European Society of Hypertension - European Society of Cardiology.- Guidelines for the management of arterial hypertension. J Hypertens, 2003, 21, 1011-1053.
6. UK Prospective Diabetes Study Group.- Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998, 317, 703-713.
7. Hansson L, Zanchetti A, Carruthers SG et al.- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 351, 1755-1762.
8. Curb D, Pressel S, Cutler J. et al.- Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA, 1996, 276, 1886-1892.
9. The ALLHAT Officiers and Coordinators for the ALLHAT Collaborative Research Group - Major outcomes in hight-risk hypertensive patients randomised to angiotensine-converting enzyme inhibitor or calcium channel blocker versus diuretic; the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288, 2981-2997.
10. Kostis J, Wilson A, Freudenberger R. et al.- Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol, 2005, 95, 29-35.
11. Tuomilehto J, Rastenyte D, Birkenhäger W. et al.-Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med, 1999, 340, 677-684.
12. Scheen A.- VALUE: analysis and results. Lancet, 2004, 364, 932-933.
13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 2000, 355, 253-259.
14. Marre M, Lievre M, Chatellier G. et al.- Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albuminin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ, 2004, 328, 495.
15. Lindholm L, Ibsen H, Dalhöf B. et al.- Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Interention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 1004-1010.
16. Schaars C, Denig P, Kasje W. et al.- Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Diabetes Care, 2004, 27, 123-128.
17. Vijan S and Hayward R.- Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Inter Med, 2003, 138, 593-602.
18. Ruggeninti P, Fassi A, Parvanova A. et al.- Preventing microalbuminuria in type 2 diabetes. N Engl J Med, 2004, 351, 1941-1951.
19. The CDC Diabetes Cost-effectiveness Group.- Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA, 2002, 287, 2542-2551.
20. Gaede P, Vedel P, Larsen N. et al.- Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-393.
21. Scheen AJ, Van Gaal LF.- Le diabète de type 2 au coeur du syndrome métabolique. Plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.